Home Featured

Featured

Random

Reclaiming Ownership of Your Body With Psychedelics

BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD

Optimi Health Announces Re-Appointments to Board of Directors

FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma...

Dissociation as Medicine? Exploring Dissociation & Dissociative Psychedelics like Ketamine

Revive Therapeutics Provides Update From Type C Meeting with FDA for...

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps...

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel...

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global...

Active vs. Passive Coping Distinguishes Antidepressants and Psychedelics

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

Psilocybin and the Will to Live

12 3...308 Page 1 of 308

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Melissa Lavasani & Jay Kopelman: Federal Psychedelic Policy, VA Pathways, and...

Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.